RxDoctor Payments Data

Jennifer McMillen, MD

Internal Medicine · Knoxville, TNNPI 1295982098

Payments from drug & device makers

$10,313in general payments, 2019–2025

Across 802 payments — averaging $12.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Abbott$624
  • Lilly USA, LLC$569
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$10,288100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,313 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$217,639
Medicare patients
456
Services billed
7,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$158,999
MounjaroTirzepatide62$101,122
EliquisApixaban76$99,605
JardianceEmpagliflozin74$98,293
TrulicityDulaglutide68$95,502
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$81,647
RybelsusSemaglutide16$33,410
JanuviaSitagliptin Phosphate18$25,227
Tresiba Flextouch U-200Insulin Degludec20$24,885
FarxigaDapagliflozin Propanediol14$22,792
XareltoRivaroxaban20$22,421
MyrbetriqMirabegron37$20,506
TradjentaLinagliptin15$18,849
Repatha SureclickEvolocumab12$15,828
Janumet XrSitagliptin Phos/Metformin Hcl11$13,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$569$196,624130 claims
Novo NordiskOzempic, Rybelsus$1,204$192,409110 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto Xr$253$121,652100 claims
PfizerEliquis, Premarin$1,057$108,992102 claims
GSKTrelegy Ellipta$147$81,64778 claims
MerckJanuvia, Janumet Xr$209$38,45629 claims
AstraZenecaFarxiga$527$22,79214 claims
Johnson & JohnsonXarelto$232$22,42120 claims
Astellas Pharma US IncMyrbetriq$149$20,50637 claims
AbbVieSynthroid$1,274$5,019112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →